By Kaakeh R, Nagel JL, Newton DW, Patel TS, Stevenson JG

Abstract Studies evaluating rapid diagnostic testing plus antimicrobial stewardship intervention have consistently demonstrated improved clinical outcomes for patients with bloodstream infections. However, the cost of implementing new rapid diagnostic testing can be significant, and usually does not generate additional revenue. There is minimal data evaluating the financial impact of adding MALDI-TOF for rapid organism identification and dedicating pharmacy stewardship personnel time, on the total hospital costs.

Read the full text here.

Share this on Twitter: